Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748420 · ClinicalTrials.gov registry record · NA
Medication Adherence Clinical Decision Support
A NA study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- NA
- Development phase
- 5,421
- Enrollment target
NCT03748420: Completed NA study, sponsored by HealthPartners Institute.
NCT03748420 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 5,421 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (286% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03748420, a NA study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 5,421 participants
- Enrollment target
Study Summary
More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States. Primary care providers (PCPs) often fail to identify medication nonadherence and/or have insufficient time and training to address underlying reasons for it. In this project, we propose a patient-centered and technology-driven strategy to identify patients with adherence issues and apply a team approach to help them achieve evidence-based personalized goals for glucose, blood pressure, or lipids. This intervention extends the use of a widely available clinical decision support (CDS) infrastructure to support a model of care that, for the first time outside of a fully integrated care environment, will integrate pharmacists within the primary care team. The intervention relies on a continuous health informatics loop to do the following: (a) identify high-risk patients with adherence problems at the point of care by expanding the capability of an electronic medical record (EMR)-linked CDS to identify poor adherence to medications; (b) establish and maintain an auto-populating up-to-date registry of patients identified for proactive pharmacist outreach; (c) implement a pharmacist outreach strategy based on an information-motivation-behavioral (IMB) framework recommended by the World Health Organization (WHO) with demonstrated ability to influence adherence across a variety of clinical applications; and (d) coordinate care and adherence information by incorporating pharmacist assessment and action plans into CDS at subsequent office encounters.
Primary Outcome
Number of patients who achieve a proportion of days covered (PDC) greater than or equal to 80% for at least one antihypertensive medication in each currently prescribed blood pressure medication class at 12 months following the index office visit date.
Interventions
- OTHER Adherence Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,421 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
What the finished NCT03748420 record still lists
NCT03748420 is an interventional study that assigns participants to a tested intervention. Its 5,421 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (286% higher).
The record links to 0 conditions, and to 1 intervention - of which Adherence Intervention is the first listed.
NCT03748420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03748420 about?
NCT03748420 is a clinical study titled "Medication Adherence Clinical Decision Support". More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States. Primary care providers (PCPs) often fail to identify medication nonadherence and/or have ins...
What is the current status of trial NCT03748420?
This trial is currently completed. It is a NA study. The enrollment target is 5,421 participants. The study started on 2020-08-19. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03748420?
The interventions under investigation include: Adherence Intervention (OTHER).
Who is sponsoring clinical trial NCT03748420?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03748420's enrollment target sits among peer trials
5,421 24th of 2000 higher than 1,977 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI